Notably, mechanistic studies revealed that metarrestin’s tumor-suppressive effects stem from its unique dual action: (1) disrupting eEF1A2-dependent ribosome biogenesis (via Pol I inhibition) to impair cancer cell proliferation, and (2) reducing metastatic dissemination by selectively targeting PNCs in invasive cells [44]. The gene discussed is EEF1A2; the disease is neoplasm.